I can now confirm the accuracy of all figures in this chart, by which I mean that the figures match those that appear in peer-reviewed journals:
Sema: Lau, et al. (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J. Med. Chem. 58(18), 7370, https://doi.org/10.1021/acs.jmedchem.5b00726 .
Tirz: Gallwitz 2022). Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers Endocrinology, 13. https://1drv.ms/b/c/d63cedb6db1eefc3/EVcJTzp22tlOpgC-BljeLwYBrV95D-jIo9oZZutP0fOtRg?e=lWcfh7 .
Reta: Coskun, et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss - From discovery to clinical proof of concept. Cell Metabolism 34(9), P1234, table S1, https://1drv.ms/b/c/d63cedb6db1eefc3/EQBjvb7zmcFFiOHjLhT6TOUBXP5mioXDS81Qu2z6ZRP1IA?e=kvvkwF .
Maz: Chen, et al. (2021). 682-P - Novel Dual Glucagon and Glucagon-Like Peptide-1 Receptor Agonist LY3305677 Improves Glucose Control, Reduces Body Weight, and Increases Energy Expenditure in Mice. Diabetes 70 (Supp.), https://doi.org/10.2337/db21-682-P .
Survo: Zimmerman, et al. (2022). BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Molec. Metabolism 66, 101633, https://www.sciencedirect.com/science/article/pii/S2212877822002022 .